Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Salicylsalicylic acid phosphatidylcholine - J & D Pharmaceuticals

Next Previous
Drug Profile

Salicylsalicylic acid phosphatidylcholine - J & D Pharmaceuticals

Alternative Names: JD-005 - J & D Pharmaceuticals

Latest Information Update: 28 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator J & D Pharmaceuticals
  • Class Non-opioid analgesics; Nonsteroidal anti-inflammatories; Salicylates
  • Mechanism of Action NF-kappa B inhibitors; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Progeria; Laminopathies
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Autosomal dominant polycystic kidney disease; Postoperative pain; Traumatic brain injuries

Most Recent Events

  • 11 Nov 2025 Salicylsalicylic acid phosphatidylcholine - J & D Pharmaceuticals receives Orphan Drug status for Laminopathies in USA (J & D pharmaceuticals pipeline, November 2025)
  • 11 Nov 2025 Salicylsalicylic acid phosphatidylcholine - J & D Pharmaceuticals receives Orphan Drug status for Progeria in USA (J & D pharmaceuticals pipeline, November 2025)
  • 10 Nov 2025 Preclinical trials in Autosomal dominant polycystic kidney disease in USA (unspecified route), prior to October 2025 (J & D pharmaceuticals pipeline, November 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top